Pegcetacoplan-Empaveli common side effects and how to deal with them

Pegcetacoplan is a subcutaneously administered C3 complement inhibitor used to treat PNH and certain C3-mediated glomerular diseases. In clinical practice, Pegtak is generally well tolerated, but there are still some common side effects that require the joint attention of medical staff and patients. According to overseas clinical studies and post-marketing drug surveillance data, the most common adverse reactions occur with an incidence rate of ≥10%, including injection site reactions, infection, diarrhea, abdominal pain, respiratory tract infection, limb pain, hypokalemia, fatigue, viral infection, cough, joint pain, dizziness, headache, and rash.

Injection site reactions usually manifest as localized redness, swelling, pain, or itching, which usually resolve within hours to days. Response options include changing the injection site, applying cold compresses to the area, and using over-the-counter pain relievers. Regarding infections, because pegnata inhibits the complement system, patients may be more susceptible to bacterial or viral infections, especially pneumococcal or influenza-related infections. Therefore, it is necessary to evaluate the vaccination status before treatment and supplement vaccination if necessary, while closely monitoring body temperature and infection symptoms.

Diarrhea and abdominal pain are usually mild to moderate and may be relieved with dietary modification and symptomatic treatment. Hypokalemia and fatigue require regular blood monitoring and electrolyte supplementation or drug dosage adjustment if necessary. Symptoms such as dizziness, headache, joint pain, and limb pain can generally be controlled with rest, appropriate exercise, and over-the-counter medications.

Generally speaking, most of the adverse reactions of Pegtak are controllable. Through regular follow-up, laboratory indicator monitoring and individualized supportive treatment, most patients can use it safely for a long time. Medical staff should inform patients in detail about potential side effects and countermeasures before treatment to help patients establish a reasonable self-monitoring plan, improve compliance and ensure maximum efficacy.

Reference materials:https://empaveli.com/